Bain Capital Life Sciences Investors as of Dec. 31, 2024
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 26 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 32.4 | $276M | 11M | 25.70 | |
| Nuvalent Inc-a (NUVL) | 13.3 | $113M | 1.4M | 78.28 | |
| Pharvaris N V (PHVS) | 7.4 | $63M | 3.3M | 19.17 | |
| Disc Medicine (IRON) | 7.3 | $62M | 984k | 63.40 | |
| Dianthus Therapeutics (DNTH) | 6.9 | $59M | 2.7M | 21.80 | |
| Savara (SVRA) | 5.3 | $45M | 15M | 3.07 | |
| Olema Pharmaceuticals (OLMA) | 5.1 | $44M | 7.5M | 5.83 | |
| Upstream Bio (UPB) | 4.4 | $38M | 2.3M | 16.44 | |
| Annexon (ANNX) | 3.2 | $27M | 5.2M | 5.13 | |
| Cidara Therapeutics Com New (CDTX) | 2.2 | $19M | 703k | 26.88 | |
| Solid Biosciences Com New (SLDB) | 1.9 | $16M | 4.0M | 4.00 | |
| Kyverna Therapeutics (KYTX) | 1.5 | $13M | 3.4M | 3.74 | |
| X4 Pharmaceuticals | 1.5 | $12M | 17M | 0.73 | |
| Mersana Therapeutics | 1.5 | $12M | 8.7M | 1.43 | |
| Tango Therapeutics (TNGX) | 1.0 | $8.4M | 2.7M | 3.09 | |
| Atea Pharmaceuticals (AVIR) | 1.0 | $8.3M | 2.5M | 3.35 | |
| Rapid Micro Biosystems Class A Com (RPID) | 0.9 | $7.6M | 8.4M | 0.90 | |
| Cabaletta Bio (CABA) | 0.7 | $6.3M | 2.8M | 2.27 | |
| Century Therapeutics (IPSC) | 0.6 | $5.5M | 5.4M | 1.01 | |
| Xilio Therapeutics (XLO) | 0.5 | $4.4M | 4.6M | 0.95 | |
| C4 Therapeutics Com Stk (CCCC) | 0.5 | $4.0M | 1.1M | 3.60 | |
| Nautilus Biotechnology (NAUT) | 0.3 | $3.0M | 1.8M | 1.68 | |
| Marinus Pharmaceuticals Com New | 0.2 | $1.4M | 2.7M | 0.54 | |
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.2 | $1.4M | 100k | 14.25 | |
| Adagio Therapeutics (IVVD) | 0.1 | $797k | 1.8M | 0.44 | |
| Syros Pharmaceuticals Com New (SYRS) | 0.1 | $632k | 2.8M | 0.23 |
